All Medimmune articles
-
BusinessPharmaceuticals roundup 2018
Merger deals, product approvals and infrastructure changes have been overshadowed by political uncertainty, in Europe and around the world
-
BusinessExpanding precision medicine beyond cancer
Exclusive interview with Koustubh Ranade, vice president of R&D at MedImmune
-
BusinessAstraZeneca sheds multiple drugs
Spate of licensing deals for non-core products as firm further tightens R&D focus
-
BusinessPfizer to buy Astrazeneca’s antibiotics
Deal tops up Pfizer’s late-stage development pipeline, but AZ will retain biological programmes
-
BusinessStandard antibody will bolster biopharma
New NIST reference material will help validate and compare analytical techniques
-
FeaturePharma queues up for checkpoint inhibitor collaborations
Combinations of different firms’ drugs seek to reap immuno-oncology’s benefits
-
Business
AstraZeneca to spin off anti-infectives research
Early-stage research will transfer to a new company, while AZ and MedImmune retain late-stage programmes
-
Business
Clinical collaborations drive cancer immunotherapy
Companies race to pair up chemotherapy drugs with immune system-boosting antibodies to greatest effect in trials
-
BusinessPharma vies to unleash immune system power on cancer
Immuno-oncological drugs look set to earn billions and significantly lengthen patients’ lives